Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in inhaled corticosteroids.

Gene L Colice1

  • 1Pulmonary, Critical Care and Respiratory Services, Washington Hospital Center, Washington, DC 20010, USA. Gene.Colice@Medstar.net

Allergy and Asthma Proceedings
|October 27, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary tuberculosis.

Postgraduate medicine·2017
Same author

Response.

Chest·2014
Same author

A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation.

Respiratory medicine·2014
Same author

Tiotropium in asthma: a systematic review.

Journal of asthma and allergy·2014
Same author

Counterpoint: should fibrinolytics be routinely administered intrapleurally for management of a complicated parapneumonic effusion? No.

Chest·2014
Same author

Rebuttal from Drs Colice and Idell.

Chest·2014

Inhaled corticosteroids (ICSs) control asthma by reducing airway inflammation. Ideal ICS formulations enhance lung deposition, improve efficacy, and minimize side effects for better asthma management.

Area of Science:

  • Pulmonology
  • Pharmacology
  • Drug Delivery Systems

Background:

  • Inhaled corticosteroids (ICSs) are essential for persistent asthma pharmacotherapy, targeting airway inflammation topically.
  • Clinical efficacy of ICSs depends on deposition, formulation, inhalation device, and corticosteroid properties.

Purpose of the Study:

  • To review the factors influencing ICS deposition, efficacy, and safety.
  • To discuss the characteristics of an ideal ICS for optimal asthma control.

Main Methods:

  • Literature review of ICS properties, formulations, delivery devices, and clinical outcomes.
  • Analysis of pharmacokinetic and pharmacodynamic factors affecting ICS performance and safety.

Main Results:

Related Experiment Videos

  • Small-particle ICS formulations in metered-dose inhalers with hydrofluoroalkane propellants may improve lung deposition and efficacy.
  • Lipid conjugation could enable once-daily dosing.
  • Systemic and oropharyngeal deposition are key safety concerns, influenced by serum half-life, receptor affinity, protein binding, and clearance.

    • Conclusions:

    • The ideal ICS should maximize lung deposition while minimizing upper airway deposition for enhanced efficacy and reduced side effects.
    • ICS with high protein binding and rapid clearance may offer improved systemic safety profiles.